|
| 37001891 | Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group. | Int J Gynecol Cancer | 2023 |
| 36332161 | Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. | J Clin Oncol | 2023 |
| 36763928 | Reply to R. Sun et al. | | 2023 |
| 35267497 | Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. | Cancers (Basel) | 2022 |
| 36001383 | Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant. | Clin Cancer Res | 2022 |
| 35361918 | Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. | British Journal of Cancer | 2022 |
| 34162658 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 31527166 | Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. | Clin Cancer Res | 2020 |
| 32360491 | Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. | Hum Pathol | 2020 |
| 32305099 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. | Lancet Oncol | 2020 |
| 32350695 | Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given? | Current Treatment Options in Oncology | 2020 |
| 32277253 | Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. | Arch Gynecol Obstet | 2020 |
| 33293730 | Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense? | Geburtshilfe Frauenheilkd | 2020 |
| 31324454 | Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. | Gynecol Oncol | 2019 |
| 30449719 | Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. | Gynecologic Oncology | 2019 |
| 30059451 | Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles. | Int J Gynecol Pathol | 2019 |
| 30374648 | What is the evidence for lymphadenectomy in presumed early ovarian cancer? | Arch Gynecol Obstet | 2019 |
| 30979843 | Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). | J Med Genet | 2019 |
| 31227222 | Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. | Gynecol Oncol | 2019 |
| 30905433 | Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ⿥70⿯years. | Gynecologic Oncology | 2019 |
| 31099641 | Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All? | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2019 |
| 30936122 | Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. | Clin Cancer Res | 2019 |
| 30815151 | Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. | AMIA Annu Symp Proc | 2018 |
| 29299667 | Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. | Acta Neuropathol | 2018 |
| 28159814 | Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. | Clin Cancer Res | 2017 |
| 28327917 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. | Annals of Oncology | 2017 |
| 29053726 | Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). | PLoS One | 2017 |
| 29029385 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. | Oncotarget | 2017 |
| 28006819 | Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review. | Br J Cancer | 2017 |
| 27896515 | Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. | Ann Surg Oncol | 2017 |
| 27837710 | Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. | Eur J Cancer | 2016 |
| 26807488 | Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. | Gynecol Oncol | 2016 |
| 27141067 | Neoadjuvant chemotherapy in ovarian cancer revisited. | Ann Oncol | 2016 |
| 26731724 | Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). | Gynecol Oncol | 2016 |
| 26941446 | Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. | Geburtshilfe Frauenheilkd | 2016 |
| 27468640 | Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914]. | Eur J Cancer | 2016 |
| 26590673 | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet Oncol | 2016 |
| 27561452 | Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. | Eur J Cancer | 2016 |
| 26099008 | Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. | Am J Surg Pathol | 2015 |
| 25771433 | Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients. | Eur J Cancer | 2015 |
| 25562434 | Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. | Br J Cancer | 2015 |
| 25852062 | Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. | Mol Cancer Ther | 2015 |
| 26115797 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. | Lancet Oncology, The | 2015 |
| 26067859 | European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015. | Int J Gynecol Cancer | 2015 |
| 25978292 | The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study. | Int J Gynecol Cancer | 2015 |
| 25069848 | [Histological grading of epithelial ovarian cancer. Review and recommendation]. | Der Pathologe | 2014 |
| 25341581 | Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). | Int J Gynecol Cancer | 2014 |
| 25341574 | Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. | International Journal of Gynecological Cancer | 2014 |
| 25341573 | Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. | International Journal of Gynecological Cancer | 2014 |
| 24992975 | [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies]. | Pathologe | 2014 |